Pyxis Oncology, Inc.
PYXS
$3.38
-$0.51-13.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 154.78% | -17.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.89% | -17.15% | |||
| Operating Income | -7.89% | -34.80% | |||
| Income Before Tax | -8.91% | -36.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.91% | -28.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.91% | -28.53% | |||
| EBIT | -7.89% | -34.80% | |||
| EBITDA | -8.72% | -58.23% | |||
| EPS Basic | -8.02% | -27.64% | |||
| Normalized Basic EPS | -8.03% | -35.94% | |||
| EPS Diluted | -8.02% | -27.64% | |||
| Normalized Diluted EPS | -8.03% | -35.94% | |||
| Average Basic Shares Outstanding | 0.82% | 0.70% | |||
| Average Diluted Shares Outstanding | 0.82% | 0.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||